Ejvind Mortz, as Co-Founder and Chief Operating Officer of Alphalyse, is at the forefront of advancing protein analytics in the biopharmaceutical industry. With a deep-seated passion for protein analytics, Ejvind plays a pivotal role in supporting biopharmaceutical developers in making informed decisions regarding drug substance...
Ejvind Mortz, as Co-Founder and Chief Operating Officer of Alphalyse, is at the forefront of advancing protein analytics in the biopharmaceutical industry. With a deep-seated passion for protein analytics, Ejvind plays a pivotal role in supporting biopharmaceutical developers in making informed decisions regarding drug substance and process development. His expertise encompasses a wide array of applications, including monoclonal antibodies (mAbs), vaccines, therapeutic proteins, and cutting-edge Cell & Gene therapy products.
Under Ejvind's leadership, Alphalyse has established itself as a premier contract research organization (CRO) specializing in protein analysis services tailored for biotech, pharmaceutical companies, and academic institutions. The company leverages advanced mass spectrometry techniques to provide comprehensive protein identification, characterization, and quantification. This analytical prowess is crucial for the manufacturing and process development of biopharmaceutical proteins, ensuring that clients can navigate the complexities of protein chemistry with confidence.
Ejvind's extensive skill set includes protein characterization, host cell protein analysis, and analytical methods development, all conducted in compliance with Good Laboratory Practice (GLP) standards. His commitment to excellence in proteomics and amino acid analysis not only enhances the reliability of the data generated but also accelerates the drug development timeline for clients. As a thought leader in the field, Ejvind Mortz continues to drive innovation at Alphalyse, empowering biopharmaceutical developers to harness the full potential of protein analytics in their quest to bring new biologic drugs to market.
